300 related articles for article (PubMed ID: 26033493)
1. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
3. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
4. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
5. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
[TBL] [Abstract][Full Text] [Related]
7. Use of flagellin and cholera toxin as adjuvants in intranasal vaccination of mice to enhance protective immune responses against uropathogenic Escherichia coli antigens.
Asadi Karam MR; Habibi M; Bouzari S
Biologicals; 2016 Sep; 44(5):378-86. PubMed ID: 27461240
[TBL] [Abstract][Full Text] [Related]
8. Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic Escherichia coli.
Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Mol Immunol; 2013 May; 54(1):32-9. PubMed ID: 23220068
[TBL] [Abstract][Full Text] [Related]
9. Construction and development of FimH lectin domain for rising immune response after injection by uropathogenic E. coli.
Zandi M; Fallah Mehrabadi J; Mahdavi M; Irani S
Hum Antibodies; 2020; 28(2):169-178. PubMed ID: 32116244
[TBL] [Abstract][Full Text] [Related]
10. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
11. In silico design of fusion protein of FimH from uropathogenic Escherichia coli and MrpH from Proteus mirabilis against urinary tract infections.
Habibi M; Asadi Karam MR; Bouzari S
Adv Biomed Res; 2015; 4():217. PubMed ID: 26605246
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
[TBL] [Abstract][Full Text] [Related]
13. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
Li X; Lockatell CV; Johnson DE; Lane MC; Warren JW; Mobley HL
Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
[TBL] [Abstract][Full Text] [Related]
14. Dimeric and Trimeric Fusion Proteins Generated with Fimbrial Adhesins of Uropathogenic
Luna-Pineda VM; Reyes-Grajeda JP; Cruz-Córdova A; Saldaña-Ahuactzi Z; Ochoa SA; Maldonado-Bernal C; Cázares-Domínguez V; Moreno-Fierros L; Arellano-Galindo J; Hernández-Castro R; Xicohtencatl-Cortes J
Front Cell Infect Microbiol; 2016; 6():135. PubMed ID: 27843814
[TBL] [Abstract][Full Text] [Related]
15. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.
Palaszynski S; Pinkner J; Leath S; Barren P; Auguste CG; Burlein J; Hultgren S; Langermann S
Dev Biol Stand; 1998; 92():117-22. PubMed ID: 9554264
[TBL] [Abstract][Full Text] [Related]
16. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
Scavone P; Sosa V; Pellegrino R; Galvalisi U; Zunino P
Microbes Infect; 2004 Jul; 6(9):853-60. PubMed ID: 15374007
[TBL] [Abstract][Full Text] [Related]
17. Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.
Li X; Erbe JL; Lockatell CV; Johnson DE; Jobling MG; Holmes RK; Mobley HL
Infect Immun; 2004 Dec; 72(12):7306-10. PubMed ID: 15557656
[TBL] [Abstract][Full Text] [Related]
18. Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.
Li X; Johnson DE; Mobley HL
Infect Immun; 1999 Jun; 67(6):2822-33. PubMed ID: 10338487
[TBL] [Abstract][Full Text] [Related]
19. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.
Forsyth VS; Himpsl SD; Smith SN; Sarkissian CA; Mike LA; Stocki JA; Sintsova A; Alteri CJ; Mobley HLT
mBio; 2020 Apr; 11(2):. PubMed ID: 32345645
[TBL] [Abstract][Full Text] [Related]
20. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.
Thankavel K; Madison B; Ikeda T; Malaviya R; Shah AH; Arumugam PM; Abraham SN
J Clin Invest; 1997 Sep; 100(5):1123-36. PubMed ID: 9276729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
